ACE — Ascelia Pharma AB Cashflow Statement
0.000.00%
- SEK308.10m
- SEK258.24m
Annual cashflow statement for Ascelia Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -93.4 | -138 | -147 | -111 | -67.8 |
Non-Cash Items | 8.74 | 6.96 | 2.72 | 3.6 | 4.39 |
Other Non-Cash Items | |||||
Changes in Working Capital | -0.842 | 14.4 | 19 | -19.5 | 0.533 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -85.5 | -117 | -125 | -127 | -62.8 |
Capital Expenditures | -0.397 | -0.038 | -0.065 | 0 | 0 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 76.4 | 0 | — | 0.047 | 0 |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Cash from Investing Activities | 76 | -0.038 | -0.065 | 0.047 | 0 |
Financing Cash Flow Items | -5.29 | -13.3 | -0.084 | -0.03 | -15.2 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 92.7 | 185 | -1.1 | -0.936 | 115 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 76.2 | 76.9 | -112 | -128 | 53.4 |